



Dr Paul Ko Ferrigno
MetaLinear Ltd

Bio: Paul Ko Ferrigno obtained his BSc (Hons) from the University of York in 1992, followed by a PhD in Biochemistry at the University of Dundee with Sir Philip Cohen and Carl Smythe. After a post-doctoral stint in Pam Silver's lab at the Dana-Farber Cancer Institute in Boston, he started the Peptide Aptamer Group in 2001 in the MRC Cancer Cell Unit at the University of Cambridge, where his Group developed what has become known as Affimer technology. In 2007 he moved to the Leeds Institute of Molecular Medicine where he founded Aptuscan Ltd in 2008. Aptuscan was acquired 3 years later by Avacta Group plc and renamed Avacta Life Sciences, where he held various positions including Chief Scientific Officer. In 2017 Paul left Avacta Life Sciences to start metaLinear Ltd, applying proprietary Randomised Protein (RTein) technology to the discovery of targets that overcome antibiotic resistance (also known as AMR).